blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3266445

EP3266445 - SUSPENSION OR COMPOSITION CONTAINING NANO-COCRYSTAL AND MANUFACTURING METHOD THEREFOR [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  17.03.2023
Database last updated on 02.09.2024
FormerThe patent has been granted
Status updated on  08.04.2022
FormerGrant of patent is intended
Status updated on  24.03.2022
FormerExamination is in progress
Status updated on  18.02.2022
FormerGrant of patent is intended
Status updated on  05.10.2021
FormerExamination is in progress
Status updated on  24.02.2020
FormerRequest for examination was made
Status updated on  08.12.2017
FormerThe international publication has been made
Status updated on  01.09.2017
Most recent event   Tooltip27.10.2023Lapse of the patent in a contracting state
New state(s): MC		published on 29.11.2023  [2023/48]
Applicant(s)For all designated states
Takeda Pharmaceutical Company Limited
1-1 Doshomachi 4-chome Chuo-ku
Osaka-shi, Osaka 541-0045 / JP
[2018/02]
Inventor(s)01 / KARASHIMA, Masatoshi
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1
Muraoka-Higashi 2-chome
Fujisawa-shi Kanagawa 251-0012 / JP
02 / YAMAMOTO, Katsuhiko
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1
Muraoka-Higashi 2-chome
Fujisawa-shi Kanagawa 251-0012 / JP
03 / KOJIMA, Takashi
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1
Muraoka-Higashi 2-chome
Fujisawa-shi Kanagawa 251-0012 / JP
04 / IKEDA, Yukihiro
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1
Muraoka-Higashi 2-chome
Fujisawa-shi Kanagawa 251-0012 / JP
 [2018/02]
Representative(s)Held, Stephan
Meissner Bolte Patentanwälte
Rechtsanwälte Partnerschaft mbB
Widenmayerstraße 47
80538 München / DE
[2018/02]
Application number, filing date16758912.601.03.2016
[2018/02]
WO2016JP56236
Priority number, dateJP2015004064702.03.2015         Original published format: JP 2015040647
[2018/02]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016140219
Date:09.09.2016
Language:JA
[2016/36]
Type: A1 Application with search report 
No.:EP3266445
Date:10.01.2018
Language:EN
[2018/02]
Type: B1 Patent specification 
No.:EP3266445
Date:11.05.2022
Language:EN
[2022/19]
Search report(s)International search report - published on:JP09.09.2016
(Supplementary) European search report - dispatched on:EP15.10.2018
ClassificationIPC:A61K9/10, A61K9/16, A61K31/341, A61K31/405, A61K31/55, A61K47/16, A61K47/18, A61K47/20, A61K47/22, A61K47/32, A61K47/34, A61K47/38, A61K9/14, A61K31/522, A61P7/10, A61P25/08, A61P29/00
[2021/42]
CPC:
A61K9/146 (EP,US); A61K31/341 (US); A61K31/405 (US);
A61K31/522 (EP,US); A61K31/55 (US); A61K47/16 (EP,US);
A61K47/18 (EP,US); A61K47/20 (EP,US); A61K47/22 (EP,US);
A61K47/32 (EP,US); A61K47/34 (EP,US); A61K47/38 (EP,US);
A61K9/10 (EP,US); A61K9/145 (EP,US); A61K9/1617 (EP,US);
A61K9/1623 (EP,US); A61K9/1652 (EP,US); A61P25/08 (EP);
A61P29/00 (EP); A61P7/10 (EP) (-)
Former IPC [2018/46]A61K9/10, A61K9/16, A61K31/341, A61K31/405, A61K31/55, A61K47/16, A61K47/18, A61K47/20, A61K47/22, A61K47/32, A61K47/34, A61K47/38, A61K9/14
Former IPC [2018/02]A61K9/10, A61K9/16, A61K31/341, A61K31/405, A61K31/55, A61K47/16, A61K47/18, A61K47/20, A61K47/22, A61K47/32, A61K47/34, A61K47/38
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/02]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:SUSPENSION ODER ZUSAMMENSETZUNG MIT NANOKRISTALL UND HERSTELLUNGSVERFAHREN DAFÜR[2018/02]
English:SUSPENSION OR COMPOSITION CONTAINING NANO-COCRYSTAL AND MANUFACTURING METHOD THEREFOR[2018/02]
French:SUSPENSION OU COMPOSITION CONTENANT DES NANOCRISTAUX ET SON PROCÉDÉ DE PRODUCTION[2018/02]
Entry into regional phase30.08.2017Translation filed 
30.08.2017National basic fee paid 
30.08.2017Search fee paid 
30.08.2017Designation fee(s) paid 
30.08.2017Examination fee paid 
Examination procedure30.08.2017Examination requested  [2018/02]
30.08.2017Date on which the examining division has become responsible
07.05.2019Amendment by applicant (claims and/or description)
26.02.2020Despatch of a communication from the examining division (Time limit: M04)
07.07.2020Reply to a communication from the examining division
09.09.2021Cancellation of oral proceeding that was planned for 14.09.2021
14.09.2021Date of oral proceedings (cancelled)
06.10.2021Communication of intention to grant the patent
16.02.2022Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
16.02.2022Fee for grant paid
16.02.2022Fee for publishing/printing paid
31.03.2022Communication of intention to grant the patent
05.04.2022Receipt of the translation of the claim(s)
Opposition(s)14.02.2023No opposition filed within time limit [2023/16]
Fees paidRenewal fee
28.03.2018Renewal fee patent year 03
29.03.2019Renewal fee patent year 04
30.03.2020Renewal fee patent year 05
30.03.2021Renewal fee patent year 06
23.03.2022Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL11.05.2022
AT11.05.2022
CZ11.05.2022
DK11.05.2022
EE11.05.2022
ES11.05.2022
FI11.05.2022
HR11.05.2022
LT11.05.2022
LV11.05.2022
MC11.05.2022
NL11.05.2022
PL11.05.2022
RO11.05.2022
RS11.05.2022
SE11.05.2022
SI11.05.2022
SK11.05.2022
SM11.05.2022
BG11.08.2022
NO11.08.2022
GR12.08.2022
IS11.09.2022
PT12.09.2022
[2023/48]
Former [2023/25]AL11.05.2022
AT11.05.2022
CZ11.05.2022
DK11.05.2022
EE11.05.2022
ES11.05.2022
FI11.05.2022
HR11.05.2022
LT11.05.2022
LV11.05.2022
NL11.05.2022
PL11.05.2022
RO11.05.2022
RS11.05.2022
SE11.05.2022
SI11.05.2022
SK11.05.2022
SM11.05.2022
BG11.08.2022
NO11.08.2022
GR12.08.2022
IS11.09.2022
PT12.09.2022
Former [2023/17]AL11.05.2022
AT11.05.2022
CZ11.05.2022
DK11.05.2022
EE11.05.2022
ES11.05.2022
FI11.05.2022
HR11.05.2022
LT11.05.2022
LV11.05.2022
NL11.05.2022
PL11.05.2022
RO11.05.2022
RS11.05.2022
SE11.05.2022
SK11.05.2022
SM11.05.2022
BG11.08.2022
NO11.08.2022
GR12.08.2022
IS11.09.2022
PT12.09.2022
Former [2023/09]AT11.05.2022
CZ11.05.2022
DK11.05.2022
EE11.05.2022
ES11.05.2022
FI11.05.2022
HR11.05.2022
LT11.05.2022
LV11.05.2022
NL11.05.2022
PL11.05.2022
RO11.05.2022
RS11.05.2022
SE11.05.2022
SK11.05.2022
SM11.05.2022
BG11.08.2022
NO11.08.2022
GR12.08.2022
IS11.09.2022
PT12.09.2022
Former [2023/07]AT11.05.2022
DK11.05.2022
ES11.05.2022
FI11.05.2022
HR11.05.2022
LT11.05.2022
LV11.05.2022
NL11.05.2022
PL11.05.2022
RS11.05.2022
SE11.05.2022
BG11.08.2022
NO11.08.2022
GR12.08.2022
IS11.09.2022
PT12.09.2022
Former [2022/51]AT11.05.2022
ES11.05.2022
FI11.05.2022
HR11.05.2022
LT11.05.2022
LV11.05.2022
NL11.05.2022
PL11.05.2022
RS11.05.2022
SE11.05.2022
BG11.08.2022
NO11.08.2022
GR12.08.2022
IS11.09.2022
PT12.09.2022
Former [2022/50]AT11.05.2022
ES11.05.2022
FI11.05.2022
HR11.05.2022
LT11.05.2022
LV11.05.2022
NL11.05.2022
PL11.05.2022
RS11.05.2022
SE11.05.2022
BG11.08.2022
NO11.08.2022
GR12.08.2022
PT12.09.2022
Former [2022/49]AT11.05.2022
ES11.05.2022
FI11.05.2022
HR11.05.2022
LT11.05.2022
LV11.05.2022
NL11.05.2022
SE11.05.2022
BG11.08.2022
NO11.08.2022
GR12.08.2022
PT12.09.2022
Former [2022/48]AT11.05.2022
ES11.05.2022
FI11.05.2022
LT11.05.2022
NL11.05.2022
SE11.05.2022
NO11.08.2022
PT12.09.2022
Former [2022/47]AT11.05.2022
ES11.05.2022
FI11.05.2022
LT11.05.2022
SE11.05.2022
NO11.08.2022
PT12.09.2022
Documents cited:Search[A]US2010184792  (SOWA CHRISTIAN [DE], et al) [A] 1-13 * paragraph [0001] * * example - *;
 [ID]WO2013057169  (UNIV GENT [BE]) [ID] 1-13 * page 1, line 5 - line 13 * * page 3, line 15 - page 4, line 7 * * sentence 7 - sentence 21 * * examples 2,3 * * claims 1-15 *;
 [Y]  - KESISOGLOU ET AL, "Nanosizing - Oral formulation development and biopharmaceutical evaluation", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM, NL, (20070824), vol. 59, no. 7, doi:10.1016/J.ADDR.2007.05.003, ISSN 0169-409X, pages 631 - 644, XP022211984 [Y] 1,3-7,9-11,13 * the whole document * * abstract * * page 633, column l, line 20 - column r, line 51 * * page 635, column l, line 34 - page 636, column l, line 14 *

DOI:   http://dx.doi.org/10.1016/j.addr.2007.05.003
 [YDA]  - GOUD N RAJESH ET AL, "Novel furosemide cocrystals and selection of high solubility drug forms", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN CHEMICAL SOCIETY AND AMERICAN PHARMACEUTICAL ASSOCIATION, US, (20120131), vol. 101, no. 2, doi:10.1002/JPS.22805, ISSN 0022-3549, pages 664 - 680, XP009508307 [YD] 1,3-7,9-11,13 * the whole document * * abstract * * scheme 1 * * page 675, column r, line 1 - page 677, column r, line 21 * [A] 2,8,12

DOI:   http://dx.doi.org/10.1002/jps.22805
International search[A]JP2008503495  (Transform Pharmaceuticals, Inc.) [A] 1-13 * , claims; examples & US 2007/0299033 A1 & WO 2006/007448 A2 & EP 1765379 A2 *;
 [A]JP2008514241  (Cadbury Adams USA L.L.C.) [A] 1-13 * , claims; paragraphs [0025] to [0026]; examples & US 2006/0068059 A1 & WO 2006/039651 A1 & EP 1806980 A1 *;
 [A]JP2010538037  (BASF SE) [A] 1-13 * , claims; paragraph [0023]; paragraph [0045], production method VI; example 6 & US 2010/0184792 A1 & WO 2009/047043 A1 & EP 2197278 A1 & KR 10-2010-0061719 A & CN 101795566 A *;
 [A]JP2011529101  (University of Bradford) [A] 1-13 * , claims; examples & US 2011/0177136 A1 & WO 2010/013035 A1 & EP 2328665 A1 & CN 102202753 A *;
 [A]JP2012501971  (Vertex Pharmaceuticals Inc.) [A] 1-13 * , claims; paragraphs [0014], [0060]; examples & US 2011/0236478 A1 & WO 2010/027921 A1 & EP 2323622 A1 & KR 10-2011-0050549 A & CN 102215816 A *;
 [XA]US2012039957  (BRZECZKO ALBERT W [US], et al) [X] 11-13 * , claims; paragraphs [0023] to [0035], [0061]; examples 5, 7 & WO 2012/021819 A1 * [A] 1-10;
 [A]JP2012522026  (Tibotec Pharmaceuticals) [A] 1-13 * , claims; examples 3, 4 & US 2012/0028998 A1 & WO 2010/112411 A1 & EP 2413936 A1 & CN 102369009 A *;
 [A]WO2013147072  (TAIHO PHARMACEUTICAL CO LTD [JP]) [A] 1-13 * , claims; test example 3 & TW 201400447 A *;
 [PA]WO2015093367  (NIPPON SODA CO [JP]) [PA] 1-13* , claims; examples & TW 201526795 A *;
 [A]  - SANDER,J.R.G. et al., "Pharmaceutical Nano- Cocrystals: Sonochemical Synthesis by Solvent Selection and Use of a Surfactant", Angewandte Chemie International Edition, (20100000), vol. 49, pages 7284 - 7288, XP055477547 [A] 1-13 * , p.7284, p.7287, Experimantal Section *

DOI:   http://dx.doi.org/10.1002/anie.201002588
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.